McKesson Corporation (BVMF:M1CK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 528.84B +15.5% |
| Revenue (ttm) | 2.13T +8.8% |
| Net Income | 23.79B +45.1% |
| EPS | 194.19 +50.2% |
| Shares Out | n/a |
| PE Ratio | 22.23 |
| Forward PE | 19.03 |
| Dividend | 0.18 (0.25%) |
| Ex-Dividend Date | Aug 31, 2026 |
| Volume | 1 |
| Open | 71.95 |
| Previous Close | 71.96 |
| Day's Range | 71.95 - 71.95 |
| 52-Week Range | 55.71 - 81.78 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial numbers in USD Financial StatementsNews
McKesson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Double-digit growth was achieved in key segments, with raised EPS and AOI guidance reflecting strong momentum. The PMG acquisition enhances oncology and biopharma capabilities, while capital deployment remains focused on growth and shareholder returns. Continued expansion in specialty platforms and confidence in navigating policy changes were emphasized.
McKesson Transcript: Wells Fargo 21st Annual Healthcare Conference
Strategic focus remains on oncology, biopharma, and supply chain, highlighted by the $2.25B Precision Medicine Group acquisition, robust Q1 growth in key segments, and disciplined capital allocation. AI and technology investments, stable generics, and biosimilar opportunities support a positive outlook.
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an America...
McKesson to buy Precision Medicine Group in about $2.25 billion deal
U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global p...
McKesson raises annual profit forecast on strong growth in specialty drug business
Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses.
McKesson Earnings Call Transcript: Q1 2027
Revenue grew 8% to $105.4B and adjusted EPS rose 20% to $9.93, with three segments posting double-digit profit growth. Full-year EPS guidance was raised, supported by strong specialty and GLP-1 demand, robust cash flow, and continued capital returns.
McKesson Earnings release: Q1 2027
McKesson released its Q1 2027 earnings on August 5, 2026, summarizing the period's financial results.
McKesson Slides: Q1 2027
McKesson has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
McKesson Quarterly report: Q1 2027
McKesson has published its Q1 2027 quarterly earnings report on August 5, 2026.
McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2027 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.94 per share of common stock, a 15% increase from $0.82 per share ...
McKesson Proxy statement: Proxy filing
McKesson filed a proxy statement on June 30, 2026, providing details for shareholder voting and corporate governance matters.
McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2027 financial results after market close on Wednesday, August 5, 2026. The company will host a l...
McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
IRVING, Texas--(BUSINESS WIRE)--Last week, McKesson Corporation hosted McKesson ideaShare 2026, the company's annual event for independent community pharmacies, in Denver, Colorado.
McKesson Proxy statement: Proxy filing
McKesson filed a proxy statement on June 12, 2026, providing details for shareholder voting and corporate governance matters.
McKesson Proxy statement: Proxy filing
McKesson filed a proxy statement on June 12, 2026, providing details for shareholder voting and corporate governance matters.
McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affi...
McKesson Transcript: Bank of America Global Healthcare Conference 2026
Strong fiscal 2026 results exceeded targets, driven by specialty pharmaceuticals and operational efficiency. Biosimilars and GLP-1s are key growth areas, with automation and AI supporting margin expansion. Strategic M&A and MedSurg separation position the business for continued growth.
McKesson expects 2027 profit slightly above estimates on drug distribution strength
McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates on Thursday, as the U.S. drug distributor banks on strength in its oncology and spe...
McKesson Earnings Call Transcript: Q4 2026
Fiscal 2026 saw strong growth with revenues up 12% and adjusted EPS up 18%, driven by specialty and oncology platforms. FY27 guidance projects 12–14% EPS growth, continued capital returns, and progress on the Medical-Surgical Solutions separation.
McKesson Earnings release: Q4 2026
McKesson released its Q4 2026 earnings on May 7, 2026, summarizing the period's financial results.
McKesson Slides: Q4 2026
McKesson has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.